BACKGROUND: Patients with metastatic renal cell carcinoma (mRCC) are often elderly and have various comorbidities, including cardiovascular diseases. Although these patients have extensive co-exposure to targeted therapy and cardiovascular drugs, the impact of this co-exposure on outcomes for patients with mRCC remains unclear. OBJECTIVE: Our objective was to evaluate the association between the use of cardiovascular medication and survival of patients with mRCC. METHODS: The study included 343 consecutive patients with mRCC treated with sunitinib or pazopanib in the first line. Clinical data obtained from the Renal Cell Carcinoma Information System (RENIS) clinical registry and hospital information systems were retrospectively analyzed. Progression-free survival (PFS) and overall survival (OS) were compared according to the use of common medications, including antihypertensives (i.e., β-blockers [BBs], angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, and diuretics), acetylsalicylic acid (aspirin), statins, and proton pump inhibitors. RESULTS: The univariate Cox analysis evaluating the impact of the assessed comedications on patient survival revealed that only BBs were significantly associated with PFS (hazard ratio [HR] 0.533, p < 0.001) and OS (HR 0.641, p = 0.006). The median PFS and OS for users of BBs was 18.39 and 37.60 months versus 8.16 and 20.4 months for patients not using BBs (p < 0.001 and p < 0.001, respectively). The Cox multivariate analysis showed that the use of BBs was a significant factor for both PFS (HR 0.428, p = 0.001) and OS (HR 0.518, p = 0.001). CONCLUSIONS: The results of this retrospective study suggest that the use of BBs is associated with favorable outcomes for patients with mRCC treated with sunitinib or pazopanib in the first line.

2nd Department of Internal Medicine Faculty of Medicine and University Hospital in Pilsen Charles University E Beneše 13 Pilsen Czech Republic

Department of Oncology 1st Faculty of Medicine Charles University and Thomayer Hospital Videnska 800 Prague Czech Republic

Department of Oncology and Radiotherapy Faculty of Medicine and University Hospital in Pilsen Charles University alej Svobody 80 304 60 Pilsen Czech Republic

Department of Urology Faculty of Medicine and University Hospital in Pilsen Charles University E Beneše 13 Pilsen Czech Republic

Laboratory of Cancer Treatment and Tissue Regeneration Faculty of Medicine in Pilsen Biomedical Center Charles University alej Svobody 76 Pilsen Czech Republic

Laboratory of Tumor Biology and Immunotherapy Faculty of Medicine in Pilsen Biomedical Center Charles University alej Svobody 76 Pilsen Czech Republic

Zobrazit více v PubMed

Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11:79–87. PubMed DOI PMC

Di Lorenzo G, Autorino R, Bruni G, Cartenì G, Ricevuto E, Tudini M, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009;20:1535–42. PubMed DOI

Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103:763–73. PubMed DOI PMC

Szmit S, Zaborowska M, Waśko-Grabowska A, Żołnierek J, Nurzyński P, Filipiak KJ, et al. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib. Kidney Blood Press Res. 2012;35:468–76. PubMed DOI

Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008;19:1613–8. PubMed DOI

Weikert S, Boeing H, Pischon T, Weikert C, Olsen A, Tjonneland A, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol. 2008;167:438–46. PubMed DOI

Hamnvik OP, Choueiri TK, Turchin A. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121:311–9. PubMed DOI

Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol. 2015;26:1128–33. PubMed DOI

Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer. 2011;47:1955–61. PubMed DOI PMC

Patel VG, Oh WK, Galsky MD, Liaw BCH, Tsao CK. Effect of concurrent beta-blocker (BB) use in patients receiving immune checkpoint inhibitors for metastatic urothelial (mUC) and renal cell carcinomas (mRCC). J Clin Oncol. 2019;37:467–467. DOI

Larochelle P, Kollmannsberger C, Feldman RD, Schiffrin EL, Poirier L, Patenaude F, et al. Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents. Curr Oncol. 2012;19:202–8. PubMed DOI PMC

Buchler T, Klapka R, Melichar B, Brabec P, Dusek L, Vyzula R, et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry. Ann Oncol. 2012;23:395–401. PubMed DOI

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16. PubMed DOI

Schuller HM. Beta-adrenergic signaling, a novel target for cancer therapy? Oncotarget. 2010;1:466–9. PubMed DOI PMC

Sastry KS, Karpova Y, Prokopovich S, Smith AJ, Essau B, Gersappe A, et al. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem. 2007;282:14094–100. PubMed DOI

Wong HP, Ho JW, Koo MW, Yu L, Wu WK, Lam EK, et al. Effects of adrenaline in human colon adenocarcinoma HT-29 cells. Life Sci. 2011;88:1108–12. PubMed DOI

Drell TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat. 2003;80:63–70. PubMed DOI

Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, andMMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 2006;66:10357–64. PubMed DOI

Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, et al. Stress hormonesregulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem. 2007;282:29919–26. PubMed DOI

Cole SW, Arevalo JM, Takahashi R, Sloan EK, Lutgendorf SK, Sood AK, et al. Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl AcadSci USA. 2010;107:5681–6. DOI

Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, et al. Stress effects on FosB and interleukin-8 (IL8) -driven ovarian cancer growth and metastasis. J Biol Chem. 2010;285:35462–70. PubMed DOI PMC

Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12:939–44. PubMed DOI PMC

Chakroborty D, Sarkar C, Basu B, Dasgupta PS, Basu S. Catecholamines regulate tumor angiogenesis. Cancer Res. 2009;69:3727–30. PubMed DOI PMC

Masur K, Niggemann B, Zanker KS, Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res. 2001;61:2866–9. PubMed PMC

Guo K, Ma Q, Wang L, Hu H, Li J, Zhang D, et al. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep. 2009;22:825–30. PubMed PMC

Stiles JM, Amaya C, Rains S, Diaz D, Pham R, Battiste J, et al. Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. PLoS ONE. 2013;8:e60021. PubMed DOI PMC

Grytli HH, Fagerland MW, Fossa SD, Tasken KA. Association between use of beta- blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. 2014;65:635–41. PubMed DOI PMC

Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol. 2011;29:2635–44. PubMed DOI PMC

Botteri E, Munzone E, Rotmensz N, Cipolla C, De Giorgi V, Santillo B, et al. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat. 2013;140:567–75. PubMed DOI PMC

Lemeshow S, Sorensen HT, Phillips G, Yang EV, Antonsen S, Riis AH, et al. β-blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomark Prev. 2011;20:2273–9. DOI

Beg MS, Gupta A, Sher D, Ali S, Khan S, Gao A, et al. Impact of concurrent medication use on pancreatic cancer survival-SEER-medicare analysis. Am J Clin Oncol. 2018;41:766–71. PubMed DOI PMC

Giampieri R, Scartozzi M, Del Prete M, Faloppi L, Bianconi M, Ridolfi F, et al. Prognostic value for incidental antihypertensive therapy with beta-blockers in metastatic colorectal cancer. Medicine. 2015;94:719. DOI

Diaz ES, Karlan BY, Li AJ. Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol. 2012;127:375–8. PubMed DOI

Wang HM, Liao ZX, Komaki R, Welsh JW, Reilly MS, Chang JY, et al. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol. 2013;24:1312–9. PubMed DOI PMC

Holmes S, Griffith EJ, Musto G, Minuk GY. Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study. Cancer Epidemiol. 2013;37:881–5. PubMed DOI

Heitz F, Hengsbach A, Harter P, Traut A, Ataseven B, Schneider S, et al. Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2017;144:181–6. PubMed DOI

Johannesdottir SA, Schmidt M, Phillips G, Glaser R, Yang EV, Blumenfeld M, et al. Use of ß-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study. BMC Cancer. 2013;13:85. PubMed DOI PMC

Choi CH, Song TJ, Kim TH, Choi JK, Park JY, Yoon A, et al. Meta-analysis of the effects of beta blocker on survival time in cancer patients. J Cancer Res Clin Oncol. 2014;140:1179–88. PubMed DOI

Zhong S, Yu D, Zhang X, Chen X, Yang S, Tang J, et al. β-blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies. Eur J Cancer Prev. 2016;25:440–8. PubMed DOI

Na Z, Qiao X, Hao X, Fan L, Xiao Y, Shao Y, et al. The effects of beta-blocker use on cancer prognosis: a meta-analysis based on 319,006 patients. Onco Targets Ther. 2018;11:4913–44. PubMed DOI PMC

Neumann E, Klaiber P, Freitag K, Schwab M, Schaeffeler E, Hennenlotter J, et al. Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation. J Cancer Res Clin Oncol. 2019;145:1835–43. PubMed DOI

Parker WP, Lohse CM, Zaid HB, Cheville JC, Boorjian SA, Leibovich BC, et al. Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma. Urol Oncol. 2017;35(36):e1-36.e6.

Shyu KG, Liou JY, Wang BW, Fang WJ, Chang H. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1a and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci. 2005;12:409–20. PubMed DOI

Schiestl C, Neuhaus K, Zoller S, Subotic U, Forster-Kuebler I, Michels R, et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr. 2011;170:493–501. PubMed DOI

Manunza F, Syed S, Laguna B, Linward J, Kennedy H, Gholam K, et al. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol. 2010;162:466–8. PubMed DOI

Deng GH, Liu J, Zhang J, Wang Y, Peng XC, Wei YQ, et al. Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer model. J Exp Clin Cancer Res. 2014;33:21. PubMed DOI PMC

Boegemann M, Schlack K, Rink M, Bernhardt S, Moran M, Hubbe M, et al. Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry. Future Oncol. 2020;16:2939–48. PubMed DOI

Lalani AA, McKay RR, Lin X, Simantov R, Kaymakcalan MD, Choueiri TK. Proton pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2017;15:724–32. PubMed DOI

Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9:10–9. PubMed

Keyomarsi K, Sandoval L, Band V. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 2003;9:10–9.

Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16:508–19. PubMed DOI PMC

McKay RR, Lin X, Albiges L, Fay AP, Kaymakcalan MD, Mickey SS, et al. Statins and survival outcomes in patients with metastatic renal cell carcinoma. Eur J Cancer. 2016;52:155–62. PubMed DOI PMC